Materialise NV (MTLS) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. While there is positive growth in the Medical segment and improved profitability, challenges such as foreign exchange headwinds, macroeconomic uncertainties, and a decline in Manufacturing revenue persist. The transition to a cloud-based model in Software is promising but poses short-term risks. The Q&A highlights sector-specific growth and challenges, but management's avoidance of certain specifics adds uncertainty. With stable revenue and improved margins but persistent headwinds, the overall sentiment is neutral, suggesting minimal short-term stock movement.
Key Financial Performance
Revenue EUR 66.3 million, stable year-on-year despite significant foreign exchange headwinds. Medical revenue grew by 7% to EUR 33.2 million, Software revenues declined slightly by 1%, and Manufacturing revenue declined by 8%. Reasons include unfavorable foreign exchange movements and macroeconomic headwinds.
Gross Profit EUR 37.9 million, resulting in a gross margin of more than 57%, up from 55.3% last year. The increase reflects disciplined cost management and operational efficiencies.
Adjusted EBIT EUR 2.5 million, corresponding to a 3.7% margin, up from EUR 0.6 million in the prior year quarter. The improvement is due to disciplined cost management and a sharper focus on core growth segments.
Net Profit EUR 1.8 million or EUR 0.03 per share. Reasons include improved profitability and positive net financial income driven by currency effects and interest income.
Free Cash Flow EUR 5.7 million, driven by strong operating cash flow of almost EUR 7 million and limited capital expenditures of EUR 1.5 million.
Medical Segment Revenue EUR 33.2 million, a 7% increase year-on-year. Growth was driven by an 11% increase in Medical Devices sales, offset by a 3% decline in Medical Software due to unfavorable foreign exchange impacts.
Software Segment Revenue EUR 9.6 million, a slight 1% decline year-on-year. On a constant currency basis, revenue increased by 5%. Transition towards a cloud-based subscription model contributed to 83% recurring revenue.
Manufacturing Segment Revenue EUR 23.5 million, an 8% decline year-on-year. Sequential growth in aerospace, defense, and semicon was offset by continued weakness in prototyping demand.
Adjusted EBITDA EUR 8 million, an increase of more than 30% year-on-year, resulting in an adjusted EBITDA margin of 12.1%. The improvement reflects effective cost management and improved operating leverage.
Net Cash Position EUR 72.8 million, up by EUR 2 million compared to the start of the quarter. The increase was driven by strong free cash flow.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Custom-made PEEK implants: Materialise expanded its cranio-maxillofacial portfolio with custom-made PEEK implants, offering surgeons an alternative to Titanium. These implants are radiolucent, enabling clearer postoperative scans, and integrate seamlessly into the existing digital workflow. Available across most European countries.
OrthoView 3D Hip: Launched to enhance hip surgery planning, moving from 2D X-ray to CT scan-based planning. This provides a richer anatomical view and integrates with Materialise's ecosystem, combining OrthoView's orthopedic knowledge with Mimics technology.
CO-AM Professional: Cloud-based software for managing 3D printing operations efficiently. It centralizes AM data, enables collaboration, and supports machine-agnostic operations. Early access program conducted, with global availability expected by mid-June 2026.
Magics Print for HP: Dedicated build preparation software included with HP's MJF 1200 3D printer. Targets lower to mid-range market segments, enabling professional-grade build preparation and workflow capabilities. Available starting early 2027.
Collaboration with HP: Materialise partnered with HP to include Magics Print software with the MJF 1200 3D printer, broadening access to lower to mid-range market segments.
Sustainability achievements: Exceeded greenhouse gas reduction targets, achieving over 1,500 tons of CO2 reduction in two years. Initiatives included switching to carbon-reduced PA 12 material and utilizing solar energy at headquarters.
Profitability improvements: Adjusted EBITDA increased by over 30% year-on-year, reaching EUR 8 million with a margin of 12.1%. This was driven by cost management and operational efficiencies.
Divestment of RapidFit and Eyewear businesses: Transferred these businesses to their management teams to operate independently. Materialise retains a minority stake in the eyewear business, allowing focus on core growth segments.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Divestment of RapidFit and Eyewear businesses: The divestment of these businesses may lead to short-term operational disruptions and potential loss of revenue from these segments, impacting overall financial performance.
Foreign exchange headwinds: Unfavorable currency exchange rates, particularly a weaker U.S. dollar, negatively impacted revenue in the Medical and Software segments, potentially affecting profitability.
Macroeconomic and geopolitical uncertainty: Persistent global uncertainties could impact demand, particularly in the Manufacturing segment, which already experienced an 8% revenue decline.
Decline in prototyping demand: Weakness in prototyping demand within the Manufacturing segment could hinder revenue growth and operational efficiency.
Transition to cloud-based subscription model: The ongoing transition in the Software segment may involve challenges such as customer adoption rates and potential short-term revenue fluctuations.
Regulatory and compliance requirements: The need to meet European reporting requirements and sustainability commitments could increase operational complexity and costs.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Divestment of RapidFit and Eyewear Businesses: Materialise has transferred its RapidFit and Eyewear businesses to their respective management teams. This move allows these businesses to operate independently, focusing on their specific markets, while Materialise concentrates on its core segments.
Expansion in Medical Segment: Materialise launched custom-made PEEK implants for cranio-maxillofacial surgeries and OrthoView 3D Hip for advanced hip surgery planning. These innovations enhance the company's medical portfolio and strengthen its position in the medtech market.
Software Development and Partnerships: Materialise introduced CO-AM Professional, a cloud-based software for managing 3D printing operations, and expanded its partnership with HP to include Magics Print for HP with the MJF 1200 3D printer. This collaboration targets the lower to mid-range market segments.
Revenue Guidance for FY 2026: Materialise reaffirms its full-year revenue guidance for fiscal year 2026 in the range of EUR 273 million to EUR 283 million, despite the divestments of RapidFit and Eyewear.
Adjusted EBIT Guidance for FY 2026: The company maintains its adjusted EBIT guidance for fiscal year 2026 at EUR 10 million to EUR 12 million, emphasizing execution discipline, cost management, and capital allocation.
Macroeconomic and Geopolitical Uncertainty: Materialise anticipates macroeconomic and geopolitical uncertainty to persist throughout 2026 but remains confident in the resilience of its business fundamentals.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How are the end markets moving with the current market turmoil, and what can be expected towards H2?
A:The end markets show varied dynamics. The U.S. markets are recovering, while Europe remains soft, particularly in the automotive industry. Aerospace and defense markets are improving with positive dynamics, while the healthcare market remains healthy globally. However, U.S. academic markets are impacted by funding cuts.
Q:How significant are aerospace and defense in the total portfolio?
A:The company has not disclosed the exact percentage of total revenue from aerospace and defense. However, growth in these sectors has been higher than 20% in recent quarters, and this trend continues.
Q:Why did the margins in the Medical segment decrease by 200 bps, and is there increased competition in this segment?
A:The 28% margin in the Medical segment aligns with expectations, considering seasonality and ForEx impacts. The company sees no significant changes in competition, though the U.S. academic market faces funding cuts, which is a smaller part of the business.
Q:Is the EUR 10 million to EUR 12 million EBIT guidance based on manufacturing running at a negative or positive EBITDA for the full year 2026?
A:The guidance assumes that manufacturing EBITDA will become positive in 2026. The recent divestments will pressure the top line but are expected to positively impact EBITDA over the longer term.
Q:Review of Unclear Management Responses
A:The management avoided providing a direct answer to the question about the exact percentage of aerospace and defense in the total portfolio, stating that they have not disclosed this information.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
EUR margin
MJF
Magics Print
OrthoView Hip
Print HP
Pro
access
capital
choice
collaboration HP
currency basis
day
ecosystem
hip
implant
income EUR
launch
leverage
offering CO
patient
platform
portfolio
process
product
production
ray
reporting
scan
software
solution industry
source
surgeon
team
user machine
MTLS Transcript
Materialise NV (MTLS) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call presents a mixed outlook. While there is positive growth in the Medical segment and improved profitability, challenges such as foreign exchange headwinds, macroeconomic uncertainties, and a decline in Manufacturing revenue persist. The transition to a cloud-based model in Software is promising but poses short-term risks. The Q&A highlights sector-specific growth and challenges, but management's avoidance of certain specifics adds uncertainty. With stable revenue and improved margins but persistent headwinds, the overall sentiment is neutral, suggesting minimal short-term stock movement.
Materialise NV (MTLS) Q4 2025 Earnings Call Transcript
Unknown2-19
Despite positive factors like a share buyback program and strong revenue growth in the Medical segment, challenges persist. The Manufacturing segment struggles with profitability and macroeconomic headwinds. The Software segment faces revenue declines due to its transition. Additionally, the company's dependence on key verticals and economic uncertainties pose risks. While financial metrics show improvement, the cautious outlook on manufacturing and strategic dependencies balance out the positives, leading to a neutral sentiment.
Materialise NV (MTLS) Q3 2025 Earnings Call Transcript
Unknown10-28
The earnings call reveals several negative factors: reduced revenue guidance, geopolitical and macroeconomic challenges, unfavorable foreign exchange impacts, and declining revenues in key segments. Despite some positive elements, like growth in the Medical segment and cost control efforts, the overall sentiment is negative due to reduced guidance and ongoing uncertainties, particularly in manufacturing and defense. The Q&A session did not alleviate concerns, with management providing vague responses about future growth and profitability. The lack of clear guidance and the negative financial trends suggest a likely negative stock price reaction.
Materialise NV (MTLS) Q2 2025 Earnings Call Transcript
Unknown7-24
The earnings call presents a mixed picture: strong growth in the Medical segment and improved gross margins are positive, but significant declines in Software and Manufacturing revenues, coupled with a net financial loss, are concerning. The Q&A reveals cautious optimism about future growth, but also highlights uncertainties, especially in the Manufacturing segment. The slight downward revision in guidance and management's vague responses further temper positive sentiment, resulting in a neutral outlook for the stock price.
MTLS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
